Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.

The Journal of clinical investigation - 1 Jul 2006

Shi Qizhen, Wilcox David A, Fahs Scot A, Weiler Hartmut, Wells Clive W, Cooley Brian C, Desai Drashti, Morateck Patricia A, Gorski Jack, Montgomery Robert R

Abstract excerpt

Inhibitory immune response to exogenously infused factor VIII (FVIII) is a major complication in the treatment of hemophilia A. Generation of such inhibitors has the potential to disrupt gene therapy for hemophilia A. We explore what we believe to be a novel approach to overcome this shortcoming. Human B-domain-deleted FVIII (hBDDFVIII) was expressed under the control of the platelet-specific alphaIIb promoter in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to Blood Platelets

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor VIII

Share to Hemophilia A

Share to Hemostasis

Share to Platelet Activation

Share to Transgenes

Share to von Willebrand Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 16823491
DOI: 10.1172/JCI28416
PMCID: PMC1483176

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.PMID 16823491Read ↗

Phenotypic correction of hemophilia A by ectopic expression of activated factor VII in platelets.Semantic proximity Read ↗

Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice.Semantic proximity Read ↗

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia ASemantic proximity Read ↗

Protein-Engineered Coagulation Factors for Hemophilia Gene TherapySemantic proximity Read ↗

Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.Semantic proximity Read ↗

Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.Semantic proximity Read ↗

Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice.Semantic proximity Read ↗

Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.Semantic proximity Read ↗

The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression.Semantic proximity Read ↗

The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.Semantic proximity Read ↗

Platelet-Targeted Gene Therapy for HemophiliaSemantic proximity Read ↗

Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.